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elements across disciplines and scientific boundaries rather
than the chance discovery of some new basic knowledge.
The artificial valve was no exception and resulted from an
intense and focused collaboration between me, then
a very young heart surgeon, and Lowell Edwards, an elderly
retired mechanical engineer (Figure 1).
It was 1958, and our clinical open-heart program in Port-
land, Oregon, was in its start-up phase. We had an active an-
imal laboratory and could take on the project. Edwards
wanted to develop an artificial heart, and I suggested one
valve at a time, starting with the mitral. Individual aortic
leaflets were already available, but mitral valve disease
was a huge unsolved problem. We started with the pooling
of our knowledge and developed an inventory of what we
already knew. We did not have to really invent a valve—
we needed only to find the best materials and the appropri-
ate geometry. Only a few materials were available for
human implantation: Dacron and Teflon as used in vascular
grafts; Silicon rubber (Silastic; Dow Corning, Midland,
Mich) as used in shunts for hydrocephalus; acrylic as
used in the Hufnagel valve designed for the descending
aorta; and stainless steel and Stellite 21 (Vitallium; Dents-
ply Austenal, York, Pa) used in orthopedics. For use in
animals, the start-up questions were as follows:
 Could these materials be used in a valve structure as
a durable implant?
 Could we implant the device using a suture technique?
 Are chordae tendineae necessary for left ventricular
function?
 Would left ventricular function be impaired if a rigid
device was connected to the annulus, preventing annu-
lar contraction?
 Would it be possible to achieve firm and lasting fixa-
tion in a moving heart?
 Would the valve be subject to thrombotic interference
with function?
Later, to go from animal to human there would be other
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1226 The Journal of Thoracic and Cardiovascular SurThe first valves were Silastic leaflets mounted in a rigid
Teflon O-ring and surrounded by a single-layer Dacron
cloth sewing margin (Figure 2, A). We had a brief learning
curve for the animal operation itself and then achieved pre-
dictable survival for a few days until thrombotic obstruction
and partial dehiscence, or both, occurred (Figure 2, B). Left
ventricular function was good, and we knew early on that
a rigid device could function in place of a more flexible liv-
ing structure. Partial valve dehiscence occurred frequently
and was addressed by sewing ring redesign. With multiple
layers of Teflon cloth acting as a cushion, we were able to
achieve perfect coaptation. The zone of coaptation was
made as large as possible to enhance stability and fibrous in-
growth (Figure 2, C). Now we had only the problem of early
thrombosis. Clot formed at the zone of endocardial injury at
the suture line and by direct extension involved the leaflets
no matter how they were mounted (Figure 2, D).
The next logical step was to avoid leaflets entirely and
use a moving, free-floating poppet as in a ball valve. This
extended survival from 2 days to approximately 1 month.
One dog, however, survived for many years. Now we could
observe healthy animals with good cardiac function up to
the time of their sudden death from thrombotic occlusion.
Encouraged by our lone survivor, we kept up the implanta-
tion rate at 2 to 3 animals per week, but we were at an
impasse. Finally, in February 1960, while running up the
stairs to the research building at the University of Oregon
Medical School (now Oregon Health & Science Univer-
sity), my mind wandered, seeing the beautiful cherry blos-
soms around the entrance, and all of a sudden I had a eureka
moment—why not cover the suture line with a retractable
Silastic shield to prevent thrombus from reaching the valve
orifice? It worked! We soon had a kennel full of happy dogs,
one of whom licked the hand of the visiting chief of cardi-
ology. I was planning to study the dogs over the next fewgery c December 2010
FIGURE 2. Leaflet type valves before implantations (A, C) and thrombosed after implant (B, D).
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lism, hemolytic anemia, and infection. But both the chief of
cardiology, Herbert Griswold, and the chief of surgery, Burt
Dunphy, insisted that we proceed to human implantation.
To go from animal to human, we were now faced with
a new set of problems. The Food and Drug Administration
was not involved with implantable devices, and there were
no guidelines. We were on our own to design a clinical trial.
Our first move was to develop an interdisciplinary team
to select patients for operation and to provide continuous
care postoperatively. The team included cardiologists, anes-
thesiologists, nephrologists, hematologists, neurologists,
and even a psychiatrist.
Only high-risk patients with intractable congestive heart
failure were selected for the initial implants. We had no in-
tensive care unit and started one for this project. Most of the
patients would require long-term ventilatory support, and
without indwelling endotracheal tubes for long-term use
we had to use tracheostomy and special volume-cycling res-
pirators. We literally mobilized the whole medical school
faculty for this project.
We had to choose an operative approach and tried
left thoracotomy, right thoracotomy, and finally midline
sternotomy.
There were ethical issues to address as well. Written in-
formed consent was not at that time part of ordinary prac-
tice. We wrote our own. In addition, we committed to
lifetime follow-up of the patients with sound statistical
analysis.1 Edwards, who was making the valves by hand,
would have to form a company and address liability issues.The Journal of Thoracic and CarThe stage had to be set for continued refinement and testing
of the valve for durability.
The big issue was the choice of valve for the first patient.
Should it be the simple ball valve that achieved long-term
survival in only 1 dog of more than 50 or the shielded valve
that provided predictable long-term survival in 80% of the
cases (Figure 3)? We did not make this decision by commit-
tee consensus. I grappled with it myself and decided on the
simple device for the first implant. The thinking was this: If
we started with the simple device and it worked, we would
not have to use the more complicated valve. If it did not
work, we could then go to the more complicated valve.
However, if we started with the more complicated valve
and it worked, how would we know whether the simple
valve might also have worked? So we started with the sim-
ple valve, and the shielded valve, which was so attractive in
experimental animals and laid the ground work for our work
in humans, was never implanted in a human.
The first patient was already in the hospital and in con-
gestive failure after 2 previous attempts at reparative sur-
gery. She was 33 years old and underwent operation on
August 25, 1960.
Her left atrium was massively dilated, almost filling the
right chest. We implanted the simple device as in our sole
dog survivor. The operation was easier than in the dog,
and she was returned to the anesthesia wakeup room, now
converted to an intensive care unit, by mid afternoon. The
chief of medicine listened to her valve. I watched his mus-
tache quiver as he leaned down, stethoscope to the patient’s
chest. ‘‘Nice job, Al’’ was all he said. That evening, we satdiovascular Surgery c Volume 140, Number 6 1227
FIGURE 4. Operative mortality by implant year for mitral valves.
FIGURE 3. Original caged ball valve (left) and shielded ball valve (right).
Reflections of the Pioneers Starrher up for a portable chest x-ray. The x-ray showed an air
fluid level in the right chest thought by the radiologist to
be in the pleural space, which we thought was a small col-
lection of blood and air outside the lung. Later that night,
she expressed a desire to lie on her right side. While I was
helping her, she gasped and died suddenly in my arm. Un-
fortunately, the air fluid level was inside the heart itself.
The cause of death was massive air embolism. Pledging
to myself that I would never let that happen again, I was
able to sleep that night.
Less than a month later, on September 21, 1960, we
operated on our second patient, a 52-year-old man. He
also had 2 previous attempts for repair for calcified mitral
stenosis.
He survived easily with only 1 complication—transient
jaundice, cause unknown but possibly from anesthetic tox-
icity. We continued the series of implants with approxi-
mately 2 patients per month. Operative mortality
decreased from approximately 50% in 1960 to less than
10% in 1965 (Figure 4). An early problem was prosthetic
valve endocarditis. However, by reorchestrating the sterile
technique in the operating room and treating both the pa-
tient and the team as potential staphylococcus carriers, we
came close to eliminating early infection. Our first report
was given to the American Surgical Association in the
spring of 1961 and published in the Annals of Surgery.2 A
similar presentation was given at the spring meeting of
the American Association for Thoracic Surgery. There
was enormous international interest, and we now had an ob-
ligation to run clinical trials at many other medical centers,
with Edwards keeping close track of their results as well as
our own.
With Edwards Laboratories (now Edwards Lifesciences,
Irvine, CA) established in California in 1960, we were able
to rapidly improve the device as we learned from our expe-
rience.1228 The Journal of Thoracic and Cardiovascular SurAccelerated fatigue tests demonstrated durability to be-
yond 40 years without prosthetic damage. All of the modi-
fications of design took into account the lubricity of blood
as measured by Edwards early in our animal experience.
A major design constraint was to be certain that the force
of ball contact with the cage would never exceed that al-
lowed by blood as a lubricant. Red blood cell survival
was diminished but not enough to cause hemolytic anemia
unless there was a perivalvular leak. Thus, in a sense the
prosthesis could injure red cells but not itself. A major
goal of the various stages in development of the mitral pros-
thesis was to diminish the amount of metallic material ex-
posed to the blood because thrombus on a metallic
surface could break off and produce an embolic event. It
took us 6 years with multiple sequential changes to arrive
at the final design (Figure 5).
After our presentation at the American Association for
Thoracic Surgery meeting, I visited Dwight Harken to
watch an aortic valve replacement and realized that his de-
vice could be improved dramatically with good engineer-
ing support. We began a crash program to modify thegery c December 2010
FIGURE 5. Evolution of the Starr–Edwards mitral valve from 1960 to 1966.
Starr Reflections of the Pioneersmitral design to function as an aortic prosthesis. The sew-
ing ring configuration was extended downstream from the
prosthesis and was more suitable for the aortic annulus.
The number of struts was reduced to 3 so they could be
lined up with the commissures of the natural valve. This
helped to limit the possibility of an embolic event from
thrombus on a strut entering the coronary ostia that are
far from the valve commissures. It also allowed the poppet
to be removed during implantation to provide better vision
of the site and reinserted after the device was sewn into
place. Our first clinical experience with the aortic valve
was in September 1961.3
Once we had the aortic valve, multiple valve replace-
ments became possible. Modern cardioplegia was not yet
available, and we used pure cold blood intermittently per-The Journal of Thoracic and Carfused through the coronary ostia with handheld cannula.
We performed our first triple valve replacement in 1963
and showed the movie at the meeting of the American
Association for Thoracic Surgery that year, to a standing
ovation.4 This was just the beginning, and the rest is inter-
esting and well documented in the literature.References
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